Wilbert Jorgam Ramos-Mamani

Wilbert Jorgam Ramos-Mamani

Auto-generated profile, based on publicly available information

Wilbert Jorgam Ramos-Mamani


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
RARoberto Alfonso Accinelli
Roberto Alfonso Accinelli
CPCesar Eduardo Malca Polo
Cesar Eduardo Malca Polo
KEKevin Jesus Salas Espinoza
Kevin Jesus Salas Espinoza
WMWilbert Jorgam Ramos Mamani
Wilbert Jorgam Ramos Mamani
Objective: The objective was to determine whether individuals who received doxycycline had a shorter hospitalization time. Methods: A retrospective, observational, and comparative study was conducted with 64 patients diagnosed with dengue. One group received standard symptomatic treatment, while the other also received doxycycline (initial dose of 200 mg, followed by 100 mg every 12 hours until discharge). Clinical and laboratory variables were compared. Results: Compared to patients who received only the standard treatment, patients treated with doxycycline had a shorter hospitalization time (26.30 ± 13.72 vs 93.18 ± 25.29 h, p<0.0001), hours of fever (13.79 ± 16.18 vs 127.08 ± 51.22, p<0.0001), headache (16.30 ± 19.27 vs 94.59 ± 26.11, p<0.0001), and myalgia (23.94 ± 10.90 vs 120.24 ± 25.20, p<0.0001). Furthermore, the doxycycline group exhibited a higher platelet recovery rate (0.54 ± 0.49 vs 0.23 ± 0.29, p=0.003) than the other group. No adverse effects were reported. Despite limitations (sample size and lack of randomization), the findings suggest that doxycycline would be a promising and useful therapeutic alternative in the management of dengue. Conclusion: The use of doxycycline in dengue treatment was associated with a reduction in hospitalization time, duration of symptoms, and a higher platelet recovery rate.

31 December 2024 in Revista de la Sociedad Peruana de Medicina Interna
Verified
Journal Article
Closed access
WRWilbert Jorgam Ramos-Mamani
Wilbert Jorgam Ramos-Mamani
HRHarold Fabian Ramos-Mamani
Harold Fabian Ramos-Mamani
GLGiovani Fabrizio Luna-Venturo
Giovani Fabrizio Luna-Venturo
GMGuiliana Mas-Ubillus
Guiliana Mas-Ubillus
Introducción: La automedicación es una práctica mundialmente común, sobre todo en países con recursos limitados en salud. Durante la pandemia, su práctica fue impulsada, exponiendo a la población a riesgos potenciales. Objetivo: Determinar la frecuencia de la automedicación prehospitalaria en los pacientes adultos diagnosticados de neumonía COVID-19 durante la segunda ola que ingresaron al Hospital Nacional Arzobispo Loayza (HNAL) de enero a febrero del 2021. Asimismo, determinar las características demográficas y clínicas, y la relación entre la automedicación prehospitalaria con la mortalidad. Materiales y Métodos: Se desarrolló un estudio descriptivo de corte transversal. Los datos fueron procesados mediante el programa STATA 18. El nivel de significancia estadística fue considerando p<0,05. Resultados: De 299 casos, se registró automedicación prehospitalaria en 132 pacientes (44,14%), cuya edad promedio fue de 57,09 ± 14,63 años y predominó el sexo masculino. El síntoma más frecuente fue disnea; mientras que obesidad fue la comorbilidad más común, seguida de hipertensión arterial y diabetes mellitus. Los fármacos empleados como automedicaciones más frecuentes fueron antibióticos (86,29%) y corticoides (59,79%), donde ceftriaxona (50%) y dexametasona (35,61%) fueron los más empleados. La automedicación con corticoides estuvo asociada con la mortalidad intrahospitalaria (p=0,021) junto con la edad mayor de 60 años y el SafiO2 inicial. Conclusión: La automedicación es una práctica utilizada por un sector importante de la población estudiada. El presente estudio muestra una relación existente entre la automedicación prehospitalaria con corticoides y la mortalidad intrahospitalaria.

Verified
Journal Article
Open access
PDF file
RARoberto Alfonso Accinelli
Roberto Alfonso Accinelli
CMCesar Eduardo Malca-Polo
Cesar Eduardo Malca-Polo
KSKevin Jesus Salas-Espinoza
Kevin Jesus Salas-Espinoza
WRWilbert Jorgam Ramos-Mamani
Wilbert Jorgam Ramos-Mamani
Objective: The objective of this study was to determine whether individuals with dengue who received doxycycline had a shorter hospitalization time. Methods: An observational, retrospective, and comparative study was conducted in an anonymized database with 64 hospitalized dengue patients from Clinic Fatima, Trujillo, Peru. They were diagnosed and treated according to the Peruvian Ministry of Health guidelines. Of the patients, 47 received doxycycline with an initial dose of 200 mg, followed by 100 mg every 12 h until discharge. The remaining 17 received only symptomatic treatment in accordance with Peruvian guidelines. Clinical and laboratory variables were compared between groups. Results: Both groups had similar ages, sex distribution and pre-hospitalization fever time, with dengue being the only infectious disease that they had. The doxycycline group had significantly shorter pre-hospitalization durations of headache (103.15 ± 26.30 vs. 125.68 ± 31.21 h, p = 0.009) and longer myalgia (97.02 ± 19.35 vs. 81.88 ± 19.08, p = 0.014) time. Compared to patients who received only the standard treatment, those treated with doxycycline had a shorter hospitalization time (26.30 ± 13.72 vs. 93.18 ± 25.29 h, p < 0.0001), as well as shorter durations of fever (13.79 ± 16.18 vs. 127.08 ± 51.22, p < 0.0001), headache (16.30 ± 19.27 vs. 94.59 ± 26.11, p < 0.0001), and myalgia (23.94 ± 10.90 vs. 120.24 ± 25.20, p < 0.0001). Furthermore, the doxycycline group exhibited a higher platelet recovery rate (0.54 ± 0.49 vs. 0.23 ± 0.29 × 103/µL·h−1, p = 0.003), and none of them discontinued it due to adverse reactions. Despite limitations, including the sample size and lack of randomization, the findings suggest that doxycycline may represent a promising and useful therapeutic alternative in the management of dengue. Conclusions: The use of doxycycline in dengue treatment was associated with reduced hospitalization time, shorter symptom duration, and a higher platelet recovery rate.